drugset
drugset / Trial / NCT04944121

Phase 2 Study of RSLV-132 in Subjects With Long COVID

NCT04944121 ↗

Phase 2 Completed 112 enrolled Resolve Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy (decrease in profound fatigue), safety and pharmacokinetics of RSLV-132 in subjects with long Corona Virus (COVID) syndome

Timeline

Start
2021-06-25
Primary completion
2023-10-31
Completion
2023-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject RSLV-132 Protein / enzyme biologic 10 mg/kg Intravenous

Indications

long COVID-19